Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: Does site-specificity exist?

Bone

Volumn 27, Issue 6, 2000, Pages 765-768

  Compston, J E ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; FEMALE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; VERTEBRA FRACTURE;

AGED; ALENDRONATE; CALCITRIOL; CALCIUM CHANNEL AGONISTS; CALCIUM CHANNEL BLOCKERS; ESTROGEN ANTAGONISTS; ETIDRONIC ACID; FEMALE; HIP FRACTURES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; SPINAL FRACTURES;

EID: 0033724685     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(00)00399-9     Document Type: Editorial

References (50)

1. Effect of hormone replacement therapy on muscle performance and balance in postmenopausal women
2. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures
3. Randomised trial of effect of alendronate on risk of fractures in women with existing vertebral fractures
4. Effect of tamoxifen on bone fractures in older nursing home residents
5. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women
6. Vitamin D3 and calcium to prevent hip fracture in elderly women
7. Diagnosis, prophylaxis and treatment of osteoporosis
8. Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence
9. Forearm fractures as predictors of subsequent osteoporotic fractures
10. Bone density at various sites for prediction of hip fracture
11. Risk factors for hip fracture in white women. The Study of Osteoporotic Fractures Research Group
12. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures
13. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older
14. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
15. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene
16. Long-term estrogen replacement therapy prevents bone loss and fractures
17. Osteopenia, hematopoiesis and bone remodelling in iliac crest and femoral biopsies; a prospective study of 102 cases of femoral neck fractures
18. Tamoxifen for prevention of breast cancer; report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
19. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol
20. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis
21. The effects of four years of intermittent cyclical etidronate treatment for postmenopausal osteoporosis
22. The prevention of early postmenopausal bone loss by cyclical etidronate therapy; a 2-year, double-blind, placebo-controlled study
23. The relationship between changes in femoral bone mineral density and calcium balance in patients with involutional osteoporosis tredated with human parathyroid hormone fragment (hPTH 1-34)
24. Prevention of bone loss with alendronate in postmenopausal women under sixty years of age
25. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
26. Evidence for the efficacy of drugs affecting bone metabolism in the prevention of hip fracture
27. Effect of calcitonin on vertebral and other fractures
28. Effects of sodium fluoride, vitamin D and calcium on cortical bone remodeling in osteoporotic patients
29. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
30. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
31. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis; the FAVO Study
32. Effect of intranasal calcitonin therapy on bone mass and bone turnover in early postmenopausal women; a dose-response study
33. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis; a dose-response study
34. Effect of salcatonin given intranasally on early postmenopausal bone loss
35. Irreversible bone loss in osteomalacia
36. Prevention of falls-related fractures; vitamin D reduces body sway in the elderly-a prospective, randomised, double-blind study
37. Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
38. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis
39. Involutional osteoporosis
40. Changes in bone mineral density of the proximal femur and spine with aging
41. Pre-existing fractures and bone mass predict vertebral fracture incidence in women
42. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black osteoporotic women
43. Marked decrease in trabecular bone quality after five years on sodium fluoride therapy? assessed by biomechanical testing of iliac crest bone biopsies in osteoporotic patients
44. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women
45. Treatment of postmenopausal osteoporosis with calcitriol or calcium
46. Use of cyclical etidronate and prevention of non-vertebral fractures
47. Prediction of postmenopausal fracture risk with bone mineral measurements